| scholarly article | Q13442814 |
| P2093 | author name string | Jing Zhao | |
| Dongmei Hu | |||
| R Jeremy Nichols | |||
| Christina N Mork | |||
| Elizabeth A Doggett | |||
| P2860 | cites work | Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity | Q22254785 |
| Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2) | Q24298459 | ||
| The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites | Q24313336 | ||
| 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization | Q24339094 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 | ||
| Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
| LRRK2 in Parkinson's disease: protein domains and functional insights | Q28235024 | ||
| Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease | Q28292932 | ||
| Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif | Q28475942 | ||
| The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia | Q29547174 | ||
| Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease | Q29547175 | ||
| Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study | Q29614953 | ||
| LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity | Q29615144 | ||
| The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. | Q33292556 | ||
| Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP | Q33470287 | ||
| Identification of the autophosphorylation sites of LRRK2. | Q33510233 | ||
| LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding | Q33999270 | ||
| Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities | Q35172817 | ||
| Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. | Q35780973 | ||
| Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. | Q36325784 | ||
| Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization | Q36780383 | ||
| CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity | Q37115256 | ||
| Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease | Q37139305 | ||
| Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. | Q37313530 | ||
| LRRK2 signaling pathways: the key to unlocking neurodegeneration? | Q37838572 | ||
| On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies | Q37856642 | ||
| Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway | Q38267597 | ||
| Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors | Q40236702 | ||
| Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. | Q43182013 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| phosphorylation | Q242736 | ||
| Parkinson's disease | Q11085 | ||
| P304 | page(s) | 37-45 | |
| P577 | publication date | 2011-11-11 | |
| P1433 | published in | Journal of Neurochemistry | Q6295643 |
| P1476 | title | Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition | |
| P478 | volume | 120 |
| Q49894769 | A cell death assay for assessing the mitochondrial targeting of proteins |
| Q48003270 | Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease |
| Q89611946 | Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease |
| Q47228597 | Back to the future: new target-validated Rab antibodies for evaluating LRRK2 signalling in cell biology and Parkinson's disease |
| Q92131837 | Binding of the Human 14-3-3 Isoforms to Distinct Sites in the Leucine-Rich Repeat Kinase 2 |
| Q38433725 | Cellular processes associated with LRRK2 function and dysfunction |
| Q41812724 | Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation |
| Q41020334 | Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition. |
| Q29347540 | G2385R and I2020T Mutations Increase LRRK2 GTPase Activity |
| Q38814476 | GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2. |
| Q37553863 | Identification of chaperones in a MPP+-induced and ATRA/TPA-differentiated SH-SY5Y cell PD model |
| Q24317158 | Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle |
| Q40188432 | In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2. |
| Q42372493 | Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker |
| Q47414771 | Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils |
| Q48560989 | LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease |
| Q38620229 | LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand? |
| Q96953324 | LRRK2 Phosphorylation, More Than an Epiphenomenon |
| Q51082156 | LRRK2 Phosphorylation. |
| Q41785779 | LRRK2 dephosphorylation increases its ubiquitination |
| Q28078899 | LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives |
| Q24300605 | LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status |
| Q39136594 | LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies. |
| Q38218398 | LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis |
| Q35170220 | Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955. |
| Q57174649 | Minimotifs dysfunction is pervasive in neurodegenerative disorders |
| Q100559468 | Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease |
| Q51082151 | Molecular Insights and Functional Implication of LRRK2 Dimerization. |
| Q37424089 | Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons |
| Q48192270 | Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation |
| Q99716681 | Pathogenic LRRK2 requires secondary factors to induce cellular toxicity |
| Q41163700 | Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation |
| Q38044449 | Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology. |
| Q21131229 | Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism |
| Q24309417 | Phosphorylation of LRRK2 by casein kinase 1α regulates trans-Golgi clustering via differential interaction with ARHGEF7 |
| Q38044439 | Phosphorylation of LRRK2: from kinase to substrate |
| Q47150726 | Rab29 activation of the Parkinson's disease-associated LRRK2 kinase |
| Q51082148 | Regulation of LRRK2 by Phosphatases. |
| Q28482925 | Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation |
| Q41579661 | Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells. |
| Q36015579 | Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models. |
| Q39263032 | Targeting LRRK2 in Parkinson's disease: an update on recent developments |
| Q64864674 | The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition |
| Q38044433 | The GTPase function of LRRK2. |
| Q28480459 | The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling |
| Q42509261 | The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway |
| Q47225650 | The LRRK2 signalling system |
| Q26853537 | The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease |
Search more.